2 编号：2026-003 投资者关系活 动类别 ☑ 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称 及人员姓名 工银瑞信基金管理有限公司 秦聪 马丁 国海证券股份有限公司 李宇宸 时间 2026 年 2 月 27 日 15：00-15：40 地点 电话会议 上市公司接待 人员姓名 邓百娇女士 董事、董事会秘书 吴 弘先生 证券事务代表 齐鑫鑫女士 投资者关系管理 IR 投资者关系活 动主要内容介 绍 Q1、请简要介绍一下公司的产品结构情况。 A：目前公司产品主要分为医疗器械类产品与功能性护肤 品两大板块，从剂型上主要分贴片类与非贴片类，非贴片类涵 盖水、精华、乳液、喷雾、冻干及次抛精华等多种形态。 Q2、公司非贴片类产品占比情况如何？ A：上海研发中心成立后，我们在化妆品产品方面上新速 度持续加快，产品与剂型不断丰富，在产品结构进一步完善的 同时，非贴片类产品的收入占比也在不断提升。 Q3、公司的三类医疗器械产品进展情况如何？ A：目前我们进展比较快的主要是重组Ⅲ型人源化胶原蛋 白冻干纤维、重组Ⅲ型人源化胶原蛋白贴 ...

Core Viewpoint - Fulejia, known as the "first stock of medical beauty masks," is facing significant challenges, with a reported revenue decline of 11.54% year-on-year for the first three quarters of 2025, totaling 1.297 billion yuan. The company aims to achieve at least 700 million yuan in revenue in the fourth quarter, which appears to be a considerable challenge [2]. Group 1: Business Performance and Challenges - Fulejia's revenue for the full year of 2024 was 2.017 billion yuan, indicating a need for substantial growth in Q4 2025 to meet targets [2]. - The company's medical device product revenue share has decreased from 55.54% in 2020 to 42.28% in 2024, and further down to 27.61% in the first half of 2025, highlighting a significant impact on its financial performance [9]. - The tightening of regulations regarding "medical beauty masks" has created a clearer distinction between medical devices and cosmetic products, further complicating Fulejia's market position [6][7]. Group 2: Product Development and Market Strategy - Fulejia has made progress in its Class III medical device projects, with a new product, "recombinant type III humanized collagen dressing," entering clinical stages, while other products are in various stages of development [2][4]. - The shift towards Class III medical devices is part of a broader trend among beauty brands, as many are moving away from Class II products due to market saturation and regulatory challenges [3][4]. - Fulejia's entry into the Class III market is seen as a strategy to strengthen its position in the medical beauty sector, although it is currently lagging behind competitors who have already secured Class III registrations [4]. Group 3: Transition to Cosmetics - Fulejia's cosmetics business has seen growth, with revenue surpassing that of medical devices for the first time in 2022, indicating a strategic pivot [11]. - However, the brand still faces challenges in changing consumer perceptions from a medical mask brand to a cosmetics brand, as many consumers associate Fulejia primarily with medical beauty masks [12]. - The company has encountered complaints regarding its cosmetic products, raising concerns about safety and efficacy, which could hinder its ability to attract new customers [12]. Group 4: Research and Development - Fulejia's R&D investment for the first three quarters of 2025 was 36.31 million yuan, with a R&D expense ratio of 2.8%, which, while improved, remains low compared to competitors [14]. - The company holds a total of 61 patents, but the majority are design patents, indicating a potential weakness in innovation compared to peers in the beauty industry [14]. - Balancing R&D investments between medical devices and cosmetics presents a challenge for Fulejia, as both sectors require significant resources to remain competitive [16].

Core Viewpoint - The company Fuhua (301371) is progressing in its R&D projects, with specific timelines and developments for its medical devices and injectable products outlined for 2025 [1] R&D Progress - The company has a Class III medical device, "Recombinant Type III Humanized Collagen Dressing," which has entered the clinical stage for 2025 [1] - For injectable products, the clinical trials for the "Recombinant Type III Humanized Collagen Lyophilized Fiber" project have been completed, and the company is preparing the clinical trial summary report [1] - The "Recombinant Type III Humanized Collagen Gel" project is still in the R&D phase, with plans to initiate clinical trials this year [1] - Further updates on other R&D projects will be available in the annual report scheduled for release in April [1]

Product Launch and Development - In November and December 2025, the company launched a total of 18 new products, with 9 in medical devices and 9 in cosmetics [1] - The company has a clinical-stage medical device, "Recombinant Type III Humanized Collagen Dressing," and is preparing for clinical trials for other collagen-based products [2] Financial Performance and Sales Strategy - The company is currently finalizing its financial results for 2025, with sales data impacted by adjustments in offline sales channels [2] - The transition from traditional distribution to value-driven sales models is expected to improve long-term health in offline business [2] Margin and Cost Management - The company is experiencing pressure on profit margins due to high online sales costs and adjustments in offline sales channels [4] - The fluctuation in gross margin is attributed to increased competition and changes in product mix, with plans for optimization in production, pricing, and supply chain management [2] Channel Optimization and Inventory Management - The company is optimizing its offline channels, focusing on better inventory management and strategic partnerships with service-oriented distributors [4] - Current adjustments in offline channels are expected to have manageable impacts on performance, laying the groundwork for future growth [4] Future Plans and Incentives - The company expresses a strong intention to implement an equity incentive plan as the management team evolves [4]

Core Viewpoint - The beauty and medical aesthetics industry is experiencing a stark contrast, with medical aesthetic companies facing significant pressure while domestic beauty brands are actively entering the medical aesthetics market [3][4][5] Medical Aesthetics Industry Performance - Among 22 medical aesthetics companies, 14 reported a year-on-year decline in revenue during the first half of the year, with "medical aesthetics trio" member Aimeike experiencing a decline exceeding 20% [4][5] - The medical aesthetics market has been growing rapidly, with a projected market size of nearly 3,700 billion by 2025, growing at an annual rate of 17.4% since 2020 [4] Competitive Landscape - The medical aesthetics industry is facing intensified competition, particularly in upstream raw materials and equipment, leading to declining revenues for companies like Aimeike and Haohai Biological [6][7] - The consumer market is becoming more rational, with 73% of mid-to-high-income consumers planning to reduce or maintain their medical aesthetics spending in 2024 compared to 2023 [7] Domestic Beauty Brands' Strategies - Over 20 domestic beauty companies are entering the medical aesthetics sector, with brands like Naturating and Youshiyan launching new products aimed at the medical aesthetics market [10][12] - Baijuerling has launched three medical aesthetics brands, focusing on injection regeneration, post-operative care, and medical equipment, indicating a comprehensive approach to the medical aesthetics industry [16][20] Market Challenges and Opportunities - The market for medical aesthetics is becoming increasingly competitive, with established brands like 可复美 and 薇诺娜 already dominating the "medical device" segment, making differentiation a key challenge for new entrants [22][25] - Despite the challenges, the structural adjustment in the medical aesthetics industry presents opportunities for collaboration and innovation, as companies explore new product offerings and partnerships [25][27]

Macro Economic Group - In May, US retail sales decreased by 0.9%, the largest drop since March 2023, exceeding expectations of a 0.6% decline [3] - Excluding automobiles, retail sales fell by 0.3%, while core retail sales, excluding gas stations, decreased by 0.1% [3] - The industrial production index for May showed a decrease of 0.2%, with manufacturing output slightly increasing by 0.1% [3] - US stock markets experienced declines, with the Dow down 0.7%, Nasdaq down 0.91%, and S&P 500 down 0.84% [3] - Oil prices rose by 5.4%, while gold and silver prices saw minor increases [3] Industry Comprehensive Group - Chip Qu Microelectronics signed contracts worth RMB 146 million for PCB production equipment, indicating optimism in the domestic PCB industry [5] - Major AI facility investors like Microsoft, Google, and Amazon are expected to increase capital expenditures by over $300 billion in 2025, a year-on-year growth of over 30% [5] - Taiwan's major PCB companies reported a 15% year-on-year revenue growth from January to May 2025, reflecting high industry demand [5] - BOE announced a plan to acquire a 30% stake in Xianyang Rainbow Optoelectronics for RMB 4.849 billion, which will enhance global TFT panel supply concentration [6] - The demand for TVs is expected to rise due to appliance consumption subsidies, positively impacting TFT panel profitability [6] Advanced Manufacturing Group - The recruitment for humanoid robots surged by 409%, with technical positions making up 62% of the total [8] - The robot industry is in a critical phase of technology development, with significant demand for talent in R&D and system debugging [8] - Investment strategies should focus on humanoid robot algorithms and automation, with long-term attention on full-stack technology and scenario positioning [8] - Tianqi Lithium and CATL established a lithium mining subsidiary, emphasizing resource control over procurement [9] - The establishment of the subsidiary reflects a strategic shift towards resource control in the lithium battery industry [9] Consumer Group - With summer approaching, searches for "graduation trips" have surged, particularly among young travelers [11] - Intercontinental Hotels Group has launched student-exclusive discounts and packages to cater to the rising demand from young tourists [11] - Fulejia announced the upcoming clinical trials for its collagen dressing, indicating growth potential in the medical aesthetics market [12]

Investment Rating - The report maintains a "Buy" rating for the industry [7] Core Insights - The optional consumption sector showed positive performance in the week of June 2-6, 2025, with the retail, social services, and beauty care sectors increasing by 1.29%, 2.09%, and 1.56% respectively, outperforming the Shanghai Composite Index which rose by 1.13% [15][17] - The beauty care segment saw significant growth, with Douyin's beauty category GMV reaching 23.497 billion yuan in May 2025, a year-on-year increase of 18% [3][23] - Major events included the acquisition of a 65% stake in Silky by Kids Wang for 1.65 billion yuan, and the IPO plans of several companies in the beauty and retail sectors [5][34] Market Performance - The retail, social services, and beauty care sectors ranked 15th, 9th, and 13th among 31 primary industries during the reporting week [15] - The tourism and beauty segments experienced notable gains, with the tourism sector seeing a 14.8% increase in domestic travel [26][27] Key Industry Data and News - In the beauty care sector, foreign brands dominated the top 10 beauty brands on Douyin, capturing 7 out of 10 spots [3][23] - The cultural and tourism sector reported a revenue of 14.151 trillion yuan in 2024, marking a 6% increase year-on-year [26] - The retail sector is witnessing significant developments, including the opening of Kids Wang's first ultra store in Shanghai and the successful IPO of Pitanium Limited on NASDAQ [5][34][29] Company Announcements - Kids Wang announced the acquisition of a 100% stake in Silky for 1.65 billion yuan, enhancing its market position [34] - Shanghai Jahwa revised its employee stock ownership plan to include revenue growth metrics [35] - The company Fat East reported a sales figure exceeding 10 billion yuan for the year [34][33]

Macro Dynamics - The central government plans to support 20 cities, including Beijing and Tianjin, with over 20 billion yuan for urban renewal actions, aiming to establish a sustainable urban renewal mechanism and address infrastructure shortcomings [1]. Healthcare Industry - The first domestically produced nine-valent HPV vaccine has been approved for market release in China, marking a significant development as it is the second nine-valent HPV vaccine globally, breaking a long-standing foreign monopoly [2][3]. Automotive Industry - Tesla's wholesale sales of new energy passenger vehicles in China for May were reported at 61,662 units, reflecting a year-on-year decline of 15%, while the overall new energy passenger vehicle market saw a growth of 38% [4]. Telecommunications Industry - Shenzhen is set to pilot the expansion of value-added telecommunications services, leveraging its technological and software information industry strengths to enhance digital trade and services [5]. Population Policy - Vietnam's National Assembly has passed a law amendment allowing couples to decide on the number of children and birth spacing based on various personal factors, lifting previous restrictions that limited births to one or two children [6]. Company Developments - Xunlei has completed the acquisition of Hupu, paying an initial cash consideration of 400 million yuan, with additional payments scheduled over the next two years [12]. - Cartier has confirmed a data breach affecting customer information, including names and birth dates, but not financial data, and is currently investigating the incident [13]. - Fulejia announced that its product "Recombinant Type III Humanized Collagen Dressing" has passed ethical review and is set to begin clinical trials, marking a first in the domestic market for this type of medical device [14]. - Kangfang Biotech denied allegations of selling clinical research drugs, stating that a sales representative misappropriated drugs under false pretenses, emphasizing that the drugs met strict quality management standards [15].

Group 1: Company Developments - Hainan Huatie is planning to issue shares overseas and list on the Singapore Exchange as part of its international strategy [1] - Weilian Meishi has increased its registered capital from 6,606 million USD to 8,106 million USD, a growth of approximately 23% [2] - CATL has repurchased a total of 6,640,986 A-shares, amounting to 1.55 billion RMB, representing 0.1508% of its total A-share capital [4] - WanTai Biologics has received approval for its nine-valent HPV vaccine, enhancing its product line and competitive edge [11] Group 2: Market Performance - Volvo's global sales in May decreased by 12% year-on-year, totaling 59,822 vehicles [3] - Tesla's new car registrations in Germany fell by 36.2% in May, with a total of 1,210 vehicles registered [5] Group 3: Investment and Financing - "NanShu Network Technology" has completed a 10 million RMB angel round financing to enhance its big data analysis platform and AI algorithms [6] - "JinChuang Technology" has successfully completed a 30 million RMB Series A financing to deepen core technology development and expand its talent team [7] - Asset management giant Brookfield plans to invest up to 99.1 billion USD to build an AI data center in Sweden, creating approximately 1,000 permanent jobs [8] Group 4: New Products - Nintendo's new console, Switch 2, will officially launch with a starting price of 3,889 RMB, and has already surpassed 400,000 pre-orders on JD [9] - Fulejia's new product, a recombinant type III humanized collagen dressing, has completed clinical trial registration, marking a significant step in its product development [10]

Core Viewpoint - The company Fulejia (301371) has announced that its Class III medical device, "Recombinant Type III Humanized Collagen Dressing," has passed ethical review for clinical trials and has been registered with the Heilongjiang Provincial Drug Administration, entering the clinical trial phase [1] Group 1: Product Development - The product is intended for auxiliary treatment of wound repair after laser and photon procedures, as well as for repairing skin barrier function damage in sensitive skin patients [1] - The product has completed the necessary ethical review and registration, indicating progress in its development [1] Group 2: Market Potential - There are relatively few similar medical devices and manufacturers in the aesthetic medicine field, suggesting a growing market with significant potential [1] - The domestic production and sales of similar products are increasing rapidly, reflecting a sustained growth in market demand [1]